Skip to Content

Positive clinical data from the Phase 1 trial of nexiguran ziclumeran

First clinical evidence from ongoing Phase 1 study that nexiguran ziclumeran (nex-z), an in vivo CRISPR/Cas9-based gene editing therapy, may favorably impact disease progression in transthyretin (ATTR) amyloidosis. Data was published in NEJM and presented at the 2024 American Heart Association Scientific Sessions.

Learn more
PATIENT STORIES

Milton

Living with ATTR Amyloidosis with Cardiomyopathy

News Updates

Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis

Read more

Intellia Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress

Read more

Aiming to make the impossible, possible

Our
Mission

Transforming lives of people with severe diseases by developing potentially curative genome editing treatments.

Learn more

Programs
and Pipeline

Each one of us together for patients

Learn more

Full-Spectrum Approach

Opening a new era in medicine

Learn more

Join Us

See how you can change life stories with genome editing.

Learn more